Irritable bowel syndrome (IBS) is a very common condition (incidence: 10–15% of the population) and symptoms are: abdominal pain and abdominal discomfort, associated with changes in stool frequency and form, in the absence of organic disease that is likely to explain the symptoms.
There is one variety, the so called post-inflammatory IBS, this is a variety of IBS, which occurs after episodes of inflammation.
Due to unsatisfactory results with conventional treatments, complementary and alternative medications, including food supplements and plant-derived products, are being increasingly used. Palmitoylethanolamide, as a natural anti-inflammatory supplement holds great promises. It was demonstrated in a special IBS model that PEA could counteracted the accelerated transit in IBS (the main cause for loose stools).
The authors pointed out that when given exogenously, as a supuplement, PEA reduces gastrointestinal transit and displays anti-inflammatory effects in the gut.
PEA was evaluated in the dose range 1–10 mg·kg−1 and was active at 10 mg/kg BW (see picture).
The authors made a mistake in mentioning certain names of supplements containing PEA. PEA is available in Italy as dietfood for medical purposes under the brandnames Normast and PeaVera, and in the rest of the world as the supplement PeaPure. The other names they mentioned are PEA combinations, containing herbals and PEA.
Capasso R1, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F, Di Marzo V, Izzo AA. Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels. Br J Pharmacol. 2014 Sep;171(17):4026-37. doi: 10.1111/bph.12759.